In the near future, pharmaceutical companies of Uzbekistan intend to invest more than $220 million in projects on the establishment of new and modernization of existing capacities.
According to experts, the accomplishment of the initiatives would accelerate the process of filling the domestic market with affordable, high-quality medicines and medical products, as well as introduction of flexible and transparent pricing mechanism.
The list of target parameters includes the launch of production of 162 new drugs, as well as the 2.5 time increase in the production of import substituting drugs and medical devices that are in the demand of the public and medical organizations.
This sector of the economy has raised more than $300 million of investments, including $100 million of direct foreign investments over the past decade owing to the government support. That was a significant contribution to the further expansion of drug production. Today, 35.7% of assets of pharmaceutical companies are represented by the share of foreign partners, and 64.3% – by domestic players.
Provision of the competitiveness of domestic products in foreign markets through the introduction of international quality standards has been a special focus of the industry. To date, 31 domestic companies have implemented a quality management system ISO 9001, six – the international GMP standard, and three – the GMP national standard.
The abovementioned measures have helped to scale up the export capacity of the domestic pharmaceutical enterprises. Previously, the country had to import drugs from abroad, while now the domestically produced drugs and medical products are exported to more than 20 countries, including CIS countries, the European Union and the United States. A total of 226 titles of Uzbek medicines have been registered in the abovementioned countries.
